Navigation Links
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
Date:9/4/2009

NEW HAVEN, Conn., Sept. 4 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of acute care antibiotic-resistant infections, announced today that Thomas R. Kassberg has joined the company as Chief Business Officer. In his new role, Mr. Kassberg will lead the company's business development activities.

Mr. Kassberg, age 49, joins Rib-X from Proteolix, Inc., where he served as Executive Vice President of Corporate Development, overseeing business development, corporate strategic planning and legal affairs. Prior to Proteolix, Mr. Kassberg had over a decade of experience in leadership roles in business development in the biotechnology industry, holding positions at InterMune, Inc., Plexxikon, Inc. (a company he co-founded), and SUGEN, Inc.

Mr. Kassberg began his career at Bristol-Myers Squibb where he held a variety of positions in finance, product and market analysis, and sales. Mr. Kassberg received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. from Gustavus Adolphus College in Minnesota.

"Tom joins Rib-X at a particularly important time in our growth, as we explore potential partnership opportunities for our lead antibiotic compounds, delafloxacin and radezolid, which have successfully completed multiple Phase 2 clinical trials," said Susan Froshauer, PhD, President and Chief Executive Officer of Rib-X Pharmaceuticals. "His business development experience and background are an ideal fit for what we need at this stage in our maturation."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Rib-X Granted Key Antibiotic Patent in China
2. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Womens Hall of Fame
4. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
5. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
6. AUDIO from Medialink, Boehringer Ingelheim Pharmaceuticals, Inc. & Pfizer Inc.: Coping with Chronic Obstructive Pulmonary Disease (COPD)
7. The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc.
8. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
9. MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
10. DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call
11. EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... New York, NY (PRWEB) June 19, 2013 ... Integrated Marketing Awards program is this Friday, June ... salutes the campaigns, ongoing programs and innovative people ... , For more information, visit http://www.minonline.com/ima . ... person or individual magazine title is eligible to ...
(Date:6/19/2013)... 2013 Today, Zane Benefits, Inc. published ... . Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution and health reimbursement ... as part of the Affordable Care Act (ACA), health ... available through new state health insurance exchanges. , Most ...
(Date:6/19/2013)... KS (PRWEB) June 19, 2013 The ... is common with today’s computer software, it creates questions ... form of misconduct. As an already published case shows, ... photo manipulation. , The Journal of Parasitology ... manipulation in a 2004 article published in the ...
(Date:6/19/2013)... Philadelphia, Pa. (June 19, 2013) The results of ... issue of Neurosurgery , official journal of the ... is published by Lippincott Williams & Wilkins , ... One study indicates that continuous "machine learning" using artificial ... survival in patients with advanced brain cancers. Another study ...
(Date:6/19/2013)... (June 19, 2013) In early April, senior leaders ... in Hartford, Connecticut, to discuss one question: how can ... , The preliminary results of this discussion ... Shooter Events: The Hartford Consensus ," a concept paper ... Journal of Trauma and Acute Care Surgery ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... over the high prevalence of HIV/AIDS in Karnataka and hoping ... H.D. Kumaraswamy will spend Tuesday night in the hut of ... village in Bagalkot district, 600 km from the state capital ... at around 11 p.m. and spend the night in the ...
... in the January 22 issue of Archives of Internal Medicine, ... supplements appears to increase// the level of the essential mineral ... load in patients with HIV infection. ,Advances in ... expectancy, however, strict adherence to the therapy is required to ...
... that is first to identify - which malignant blood ... experimental drugs that unleash pent-up "cell suicide" factors to ... chronic lymphocytic leukemia, CLL, which is diagnosed in 10,000 ... new drug because the cancerous cells are strongly dependent ...
... a dozen people have taken ill and have been hospitalized ... and ‘ baseless’ by spokesman Xiong Yuanda of the Health ... no infectious ‘unknown’ disease, doing the rounds in the city, ... Health bureau has sought to dispel reports carried by a ...
... breast implants done for augmentation purposes or for firming up. ... have united to offer services in this field. ... rate compared to the so called cheaper clinics. They also ... are all a highly creditable force from the British Association ...
... out with a skin patch to treat Alzheimer’s. This ... promising//. According to these researchers, the skin patch is ... is said to occur when a protein called beta ... introduced through the skin attacks beta amyloid and breaks ...
Cached Medicine News:Health News:Karnataka Chief Minister to Spend Night With HIV Positive Family 2Health News:Selenium Supplements May Suppress HIV Viral Load 2Health News:New Test Predicts CLL’s Sensitivity to Experimental Drug 2Health News:New Test Predicts CLL’s Sensitivity to Experimental Drug 3
(Date:6/19/2013)... June 19, 2013 /PRNewswire-iReach/ -- In its ... specialty pharmaceutical company dedicated to advancing development ... and sustained release drug therapies in patient ... today announced the acquisition of Enzon Pharmaceutical,s ... and associated product pipeline. Acquisition of this ...
(Date:6/19/2013)... , June 19, 2013 Today MedeAnalytics, ... introduced the next-generation of its Employer Group ... health plans to provide their employer groups an ... factors, medical and prescription drug claims, network utilization, ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group ...
(Date:6/19/2013)... may seem like an odd pairing: an oral growth hormone-boosting ... two of the most talked about topics at ENDO 2013, ... that just convened in San Francisco . ... the top internal medicine experts in the world is very ... not only save lives, but help people feel and ...
Breaking Medicine Technology:Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4
Nitinol Tipless Stone Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
Medicine Products: